PCSK9基因抑制与他汀治疗的代谢组学效应比较
本研究在PROSPER试验中量化5359例(2659例接受治疗)的228项代谢指标,并以PCSK9 rs11591147为工具在8个队列(N=72185)中模拟PCSK9抑制剂效应。按等效降低LDL-C标化后,PCSK9基因抑制对代谢标志物的总体效应与他汀一致(R²=0.88),但对VLDL胆固醇降低作用较弱(54% vs 77%,P=2x10-7),对氨基酸、酮体和GlycA无显著影响。
要点
- 按等效降低LDL-C标化,PCSK9基因抑制对228项代谢指标的整体效应与他汀高度一致(R²=0.88)。
- PCSK9基因抑制对VLDL胆固醇的降低作用弱于他汀(54% vs 77%,P=2x10-7)。
- PCSK9基因抑制对氨基酸、酮体及炎症标志物GlycA无显著影响,而他汀弱降低GlycA。
核心结论
- PCSK9基因抑制对详细脂质和代谢物谱的效应与他汀治疗相似。
- 按等效降低LDL-C标化,PCSK9抑制剂对VLDL脂质的效应预计弱于他汀,可能转化为较小的CVD风险降低。
研究设计与样本
- 在PROSPER随机试验中,于随机化后6个月用核磁共振波谱量化5359例(2659例接受治疗)的228项循环代谢指标。
- 在8个人群队列(N=72185)中以PCSK9 rs11591147作为无混杂代理指标,模拟PCSK9抑制剂的治疗效应。
主要发现
- 按等效降低LDL-C标化,PCSK9基因抑制对228项代谢标志物的效应与他汀治疗总体一致(R²=0.88)。
- 脂蛋白脂质组成和脂肪酸分布的改变相似。
- PCSK9基因抑制对VLDL胆固醇的降低作用弱于他汀(54% vs 77%,相对于对LDL-C的降低效应;异质性P=2x10-7)。
- PCSK9基因抑制对氨基酸、酮体或炎症标志物GlycA无显著影响,而他汀治疗弱降低GlycA水平。
关键数值与推荐
- 等效降低LDL-C标化下,PCSK9基因抑制与他汀对228项代谢标志物效应的R²=0.88。
- PCSK9基因抑制对VLDL胆固醇降低54%,他汀降低77%(相对于对LDL-C的降低效应;异质性P=2x10-7)。
临床怎么用
- 临床解读PCSK9抑制剂与他汀的代谢效应时,应认识到两者总体代谢谱相似,但PCSK9抑制剂对VLDL脂质的效应可能较弱。
- 对VLDL脂质相关风险较高的患者,他汀可能具有相对更强的VLDL胆固醇降低作用,但需结合临床判断。
局限性
- PCSK9抑制的效应基于遗传代理指标rs11591147模拟,非直接药物干预。
- 代谢指标为循环标志物,未直接评估临床心血管终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL-C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite profiling of a large randomized statin trial and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial. METHODS: 228 circulating metabolic measures were quantified by nuclear magnetic resonance spectroscopy, including lipoprotein subclass concentrations and their lipid composition, fatty acids, and amino acids, for 5,359 individuals (2,659 on treatment) in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial at 6-months post-randomization. The corresponding metabolic measures were analyzed in eight population cohorts (N=72,185) using PCSK9 rs11591147 as an unconfounded proxy to mimic the therapeutic effects of PCSK9 inhibitors. RESULTS: Scaled to an equivalent lowering of LDL-C, the effects of genetic inhibition of PCSK9 on 228 metabolic markers were generally consistent with those of statin therapy (R2=0.88). Alterations in lipoprotein lipid composition and fatty acid distribution were similar. However, discrepancies were observed for very-low-density lipoprotein (VLDL) lipid measures. For instance, genetic inhibition of PCSK9 had weaker effects on lowering of VLDL-cholesterol compared with statin therapy (54% vs. 77% reduction, relative to the lowering effect on LDL-C; P=2x10-7 for heterogeneity). Genetic inhibition of PCSK9 showed no significant effects on amino acids, ketones, or a marker of inflammation (GlycA) whereas statin treatment weakly lowered GlycA levels. CONCLUSIONS: Genetic inhibition of PCSK9 had similar metabolic effects to statin therapy on detailed lipid and metabolite profiles. However, PCSK9 inhibitors are predicted to have weaker effects on VLDL lipids compared with statins for an equivalent lowering of LDL-C, which potentially translate into smaller reductions in cardiovascular disease risk.
引用
- Sliz E, Kettunen J, Holmes MV, et al. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation. 2018. PMID: 30524137. doi:10.1161/CIRCULATIONAHA.118.034942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。